These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 11720891)

  • 1. Increased serum osteoprotegerin in disorders characterized by persistent immune activation or glucocorticoid excess--possible role in bone homeostasis.
    Ueland T; Bollerslev J; Godang K; Müller F; Frøland SS; Aukrust P
    Eur J Endocrinol; 2001 Dec; 145(6):685-90. PubMed ID: 11720891
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Decreased bone density, elevated serum osteoprotegerin, and beta-cross-laps in Wilson disease.
    Hegedus D; Ferencz V; Lakatos PL; Meszaros S; Lakatos P; Horvath C; Szalay F
    J Bone Miner Res; 2002 Nov; 17(11):1961-7. PubMed ID: 12412803
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteoprotegerin and bone mass in squamous cell head and neck cancer patients.
    Valero C; Olmos JM; Rivera F; Hernández JL; Vega ME; Macías JG
    Calcif Tissue Int; 2006 Jun; 78(6):343-7. PubMed ID: 16830204
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased bone resorption in HD patients: is it caused by elevated RANKL synthesis?
    Avbersek-Luznik I; Balon BP; Rus I; Marc J
    Nephrol Dial Transplant; 2005 Mar; 20(3):566-70. PubMed ID: 15665031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GH replacement therapy increases plasma osteoprotegerin levels in GH-deficient adults.
    Lanzi R; Losa M; Villa I; Gatti E; Sirtori M; Dal Fiume C; Rubinacci A
    Eur J Endocrinol; 2003 Feb; 148(2):185-91. PubMed ID: 12590637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changes in osteoprotegerin and markers of bone metabolism during glucocorticoid treatment in patients with chronic glomerulonephritis.
    Sasaki N; Kusano E; Ando Y; Nemoto J; Iimura O; Ito C; Takeda S; Yano K; Tsuda E; Asano Y
    Bone; 2002 Jun; 30(6):853-8. PubMed ID: 12052453
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized placebo-controlled trial of short-term graded transdermal estradiol in healthy gonadotropin-releasing hormone agonist-suppressed pre- and postmenopausal women: effects on serum markers of bone turnover, insulin-like growth factor-I, and osteoclastogenic mediators.
    Liu PY; Hoey KA; Mielke KL; Veldhuis JD; Khosla S
    J Clin Endocrinol Metab; 2005 Apr; 90(4):1953-60. PubMed ID: 15623811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Osteoprotegerin and bone mineral density in hemodiafiltration patients.
    Crisafulli A; Romeo A; Floccari F; Aloisi E; Atteritano M; Cincotta M; Aloisi C; Pizzoleo MA; Ruello A; Artemisia A; Valenti A; Frisina N; Teti D; Buemi M
    Ren Fail; 2005; 27(5):531-9. PubMed ID: 16152990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating osteoprotegerin and receptor activator of NF-kappaB ligand system are associated with bone metabolism in middle-aged males.
    Oh KW; Rhee EJ; Lee WY; Kim SW; Baek KH; Kang MI; Yun EJ; Park CY; Ihm SH; Choi MG; Yoo HJ; Park SW
    Clin Endocrinol (Oxf); 2005 Jan; 62(1):92-8. PubMed ID: 15638876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis.
    Sasaki N; Kusano E; Ando Y; Yano K; Tsuda E; Asano Y
    Nephrol Dial Transplant; 2001 Mar; 16(3):479-82. PubMed ID: 11239019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum osteoprotegerin and RANKL levels in chronic alcoholic liver disease.
    García-Valdecasas-Campelo E; González-Reimers E; Santolaria-Fernández F; De la Vega-Prieto MJ; Milena-Abril A; Sánchez-Pérez MJ; Martínez-Riera A; Gómez-Rodríguez Mde L
    Alcohol Alcohol; 2006; 41(3):261-6. PubMed ID: 16476762
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The changes in circulating osteoprotegerin after hormone therapy in postmenopausal women and their relationship with oestrogen responsiveness on bone.
    Han KO; Choi JT; Choi HA; Moon IG; Yim CH; Park WK; Yoon HK; Han IK
    Clin Endocrinol (Oxf); 2005 Mar; 62(3):349-53. PubMed ID: 15730418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth hormone substitution increases gene expression of members of the IGF family in cortical bone from women with adult onset growth hormone deficiency--relationship with bone turn-over.
    Ueland T; Odgren PR; Yndestad A; Godang K; Schreiner T; Marks SC; Bollerslev J
    Bone; 2003 Oct; 33(4):638-45. PubMed ID: 14555269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased serum osteoprotegerin values in long-lived subjects: different effects of inflammation and bone metabolism.
    Mazziotti G; Amato G; Sorvillo F; Piscopo M; Rizzo MR; Lalli E; Iride L; Cioffi M; Molinari AM; Paolisso G; Carella C
    Eur J Endocrinol; 2006 Mar; 154(3):373-7. PubMed ID: 16498049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Changes in the serum growth factors and osteoprotegerin after bone marrow transplantation: impact on bone and mineral metabolism.
    Baek KH; Lee WY; Oh KW; Kim HS; Han JH; Kang MI; Cha BY; Lee KW; Son HY; Kang SK; Kim CC
    J Clin Endocrinol Metab; 2004 Mar; 89(3):1246-54. PubMed ID: 15001618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum osteoprotegerin levels in patients after liver transplantation and correlation to bone turnover, bone mineral density and fracture status.
    Fahrleitner A; Prenner G; Kniepeiss D; Iberer F; Tscheliessnigg KH; Piswanger-Sölkner C; Obermayer-Pietsch B; Leb G; Dobnig H
    Wien Klin Wochenschr; 2002 Aug; 114(15-16):717-24. PubMed ID: 12602117
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased levels of osteoprotegerin in hemodialysis patients.
    Avbersek-Luznik I; Malesic I; Rus I; Marc J
    Clin Chem Lab Med; 2002 Oct; 40(10):1019-23. PubMed ID: 12476941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Osteoclastic function is accelerated in male patients with type 2 diabetes mellitus: the preventive role of osteoclastogenesis inhibitory factor/osteoprotegerin (OCIF/OPG) on the decrease of bone mineral density.
    Suzuki K; Kurose T; Takizawa M; Maruyama M; Ushikawa K; Kikuyama M; Sugimoto C; Seino Y; Nagamatsu S; Ishida H
    Diabetes Res Clin Pract; 2005 May; 68(2):117-25. PubMed ID: 15860239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Osteoprotegerin and its correlations with new markers of bone formation and bone resorption in kidney transplant recipients.
    Malyszko J; Malyszko JS; Wolczynski S; Mysliwiec M
    Transplant Proc; 2003 Sep; 35(6):2227-9. PubMed ID: 14529897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased levels of biochemical markers of bone turnover in relation to persistent immune activation in common variable immunodeficiency.
    Ueland T; Frøland SS; Bollerslev J; Aukrust P
    Eur J Clin Invest; 2001 Jan; 31(1):72-8. PubMed ID: 11168441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.